Birdwatch Note
2024-12-02 10:56:13 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
まずmRNAワクチンからの収益が主であるモデルナ・ビオンテックはその元の値で販売していた時とは一転して、今期赤字予想で巨利を得ている訳ではありません。 https://www.nikkei.com/nkd/company/us/BNTX/finance/ https://www.nikkei.com/nkd/company/us/MRNA/finance/ ワクチンは販売量が低下し商用化する中で米国で成人の民間の接種費用が2万円程(保険なし)、英国で最大2万円等と大幅値上げされ、日本同様で、それにも関わらず、上記の現状ですので、投稿は誤解を招くものです。 https://www.cdc.gov/vaccines-for-children/php/awardees/current-cdc-vaccine-price-list.html https://www.bbc.com/news/health-55045639 この大幅値上げで不当な利益論は下記記事等で説明されてますが、流通開発固定費等を考慮しておらず販売量が低い場合は価格が高くないと、損益分岐点にならないという一般論を無視しています。 https://answers.ten-navi.com/pharmanews/22591/ https://pharmaphorum.com/news/pfizer-plans-considerable-2023-comirnaty-markup
Written by 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1863519093976080574
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1863537652227858620
- noteId - 1863537652227858620
- participantId -
- noteAuthorParticipantId - 41A6243EF0C5E2F69F5A0D4006A468F4F7CBEC237CAE6ACCC5FB56ED687492FE Participant Details
- createdAtMillis - 1733136973803
- tweetId - 1863519093976080574
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- まずmRNAワクチンからの収益が主であるモデルナ・ビオンテックはその元の値で販売していた時とは一転して、今期赤字予想で巨利を得ている訳ではありません。 https://www.nikkei.com/nkd/company/us/BNTX/finance/ https://www.nikkei.com/nkd/company/us/MRNA/finance/ ワクチンは販売量が低下し商用化する中で米国で成人の民間の接種費用が2万円程(保険なし)、英国で最大2万円等と大幅値上げされ、日本同様で、それにも関わらず、上記の現状ですので、投稿は誤解を招くものです。 https://www.cdc.gov/vaccines-for-children/php/awardees/current-cdc-vaccine-price-list.html https://www.bbc.com/news/health-55045639 この大幅値上げで不当な利益論は下記記事等で説明されてますが、流通開発固定費等を考慮しておらず販売量が低い場合は価格が高くないと、損益分岐点にならないという一般論を無視しています。 https://answers.ten-navi.com/pharmanews/22591/ https://pharmaphorum.com/news/pfizer-plans-considerable-2023-comirnaty-markup
Note Ratings
| rated at | rated by | |
| 2024-12-02 17:59:52 -0600 | Rating Details | |
| 2024-12-02 17:38:09 -0600 | Rating Details | |
| 2024-12-02 17:03:09 -0600 | Rating Details | |
| 2024-12-02 16:37:08 -0600 | Rating Details | |
| 2024-12-02 15:47:57 -0600 | Rating Details | |
| 2024-12-02 13:51:17 -0600 | Rating Details | |
| 2024-12-02 13:30:40 -0600 | Rating Details | |
| 2024-12-02 12:04:36 -0600 | Rating Details | |
| 2024-12-02 11:08:53 -0600 | Rating Details | |
| 2024-12-02 10:07:19 -0600 | Rating Details | |
| 2024-12-02 08:18:28 -0600 | Rating Details | |
| 2024-12-02 08:11:39 -0600 | Rating Details | |
| 2024-12-02 08:00:58 -0600 | Rating Details | |
| 2024-12-02 07:36:28 -0600 | Rating Details | |
| 2024-12-02 07:32:27 -0600 | Rating Details | |
| 2024-12-02 07:23:15 -0600 | Rating Details | |
| 2024-12-02 07:21:27 -0600 | Rating Details | |
| 2024-12-02 06:38:43 -0600 | Rating Details | |
| 2024-12-02 06:38:16 -0600 | Rating Details | |
| 2024-12-02 06:38:07 -0600 | Rating Details | |
| 2024-12-02 06:37:25 -0600 | Rating Details | |
| 2024-12-02 06:31:32 -0600 | Rating Details | |
| 2024-12-02 06:29:18 -0600 | Rating Details | |
| 2024-12-02 06:18:14 -0600 | Rating Details | |
| 2024-12-02 06:07:04 -0600 | Rating Details | |
| 2024-12-02 06:06:51 -0600 | Rating Details | |
| 2024-12-02 05:59:49 -0600 | Rating Details | |
| 2024-12-02 05:57:31 -0600 | Rating Details | |
| 2024-12-02 05:49:43 -0600 | Rating Details | |
| 2024-12-02 05:46:36 -0600 | Rating Details | |
| 2024-12-02 05:44:40 -0600 | Rating Details | |
| 2024-12-02 05:37:09 -0600 | Rating Details | |
| 2024-12-02 05:34:25 -0600 | Rating Details | |
| 2024-12-02 05:24:34 -0600 | Rating Details | |
| 2024-12-02 05:05:55 -0600 | Rating Details | |
| 2024-12-03 21:44:47 -0600 | Rating Details | |
| 2024-12-03 07:39:11 -0600 | Rating Details | |
| 2024-12-03 07:10:06 -0600 | Rating Details | |
| 2024-12-03 04:26:26 -0600 | Rating Details | |
| 2024-12-02 21:24:51 -0600 | Rating Details | |
| 2024-12-02 20:49:20 -0600 | Rating Details | |
| 2024-12-05 22:24:34 -0600 | Rating Details | |
| 2024-12-05 21:37:35 -0600 | Rating Details | |
| 2024-12-05 17:40:54 -0600 | Rating Details | |
| 2024-12-05 14:05:17 -0600 | Rating Details | |
| 2024-12-05 11:18:43 -0600 | Rating Details | |
| 2024-12-05 09:36:49 -0600 | Rating Details | |
| 2024-12-05 09:13:05 -0600 | Rating Details | |
| 2024-12-05 09:07:56 -0600 | Rating Details | |
| 2024-12-05 08:19:52 -0600 | Rating Details | |
| 2024-12-10 18:58:01 -0600 | Rating Details | |
| 2024-12-10 01:29:52 -0600 | Rating Details | |
| 2024-12-10 01:05:26 -0600 | Rating Details |